SAB Biotherapeutics: Chardan Capital Maintains Buy Rating with Lower PT of $12

SAB Biotherapeutics: Chardan Capital Maintains Buy Rating with Lower PT of $12

SAB Biotherapeutics Inc. (SABS) continues to receive positive analyst sentiment, with Chardan Capital maintaining a "buy" rating for the company. The investment bank has revised its price target for SAB Biotherapeutics to $12 from $11.50, reflecting recent developments in the company's financial performance and operational activities.

The company reported a quarterly adjusted loss of $1.09 per share for the period ended June 30, 2025, which was lower than the same quarter last year when the company reported an EPS of -79 cents. Analysts had expected a loss of 80 cents per share, with the actual result beating the mean expectation [1].

SAB Biotherapeutics reported a quarterly loss of $10.11 million, an increase from the prior year's loss of $7.34 million. The company's net loss per share, both basic and diluted, was $1.09, compared to $0.79 in the same period last year. The company did not recognize any revenue for the three and six months ended June 30, 2025, indicating a continued focus on research and development [2].

The company's lead candidate, SAB-142, is aimed at preventing or delaying the progression of type 1 diabetes. SAB Biotherapeutics has formed a subsidiary in Australia to conduct preclinical and clinical activities, benefiting from the Australian government's tax credit program. The company has also renewed and entered into several lease agreements for lab and office space, crucial for ongoing research and development activities [2].

Chardan Capital's revision of the price target reflects the company's continued focus on developing innovative biotechnology solutions and the potential for future growth. The investment bank believes that SAB Biotherapeutics' pipeline of product candidates, particularly SAB-142, holds significant promise for addressing immune system disorders and infectious diseases.

The company's shares have seen a significant increase of 24.8% this quarter, despite a 42.3% loss year-to-date. The average analyst rating on the shares remains "buy," with no "hold" or "sell" recommendations, indicating strong investor confidence in the company's prospects [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2RC:0-sab-biotherapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.tradingview.com/news/tradingview:377fb119da3fd:0-sab-biotherapeutics-inc-sec-10-q-report/